We are live on ! Find out more
PCRX icon

Pacira BioSciences

214 hedge funds and large institutions have $3.29B invested in Pacira BioSciences in 2015 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 70 increasing their positions, 66 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

170% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 23

120% more funds holding in top 10

Funds holding in top 10: 511 (+6)

87% more capital invested

Capital invested by funds: $1.76B → $3.29B (+$1.53B)

21% more funds holding

Funds holding: 177214 (+37)

6% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 66

39% less call options, than puts

Call options by funds: $29M | Put options by funds: $47.5M

Holders
214
Holders Change
+37
Holders Change %
+20.9%
% of All Funds
5.61%
Holding in Top 10
11
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+120%
% of All Funds
0.29%
New
62
Increased
70
Reduced
66
Closed
23
Calls
$29M
Puts
$47.5M
Net Calls
-$18.5M
Net Calls Change
-$18.2M
Name Holding Trade Value Shares
Change
Change in
Stake
NCGI
26
Next Century Growth Investors
Minnesota
$35.4M +$26.1M +461,422 New
Millennium Management
27
Millennium Management
New York
$32.4M -$5.08M -89,713 -18%
Adage Capital Partners
28
Adage Capital Partners
Massachusetts
$30.7M +$22.6M +400,000 New
DM
29
Deerfield Management
New York
$28.5M -$18.8M -331,485 -47%
ECP
30
Elk Creek Partners
Colorado
$26.5M -$1.65M -29,073 -8%
Wells Fargo
31
Wells Fargo
California
$24.8M +$15.9M +280,924 +661%
VOYA Investment Management
32
VOYA Investment Management
Georgia
$24.8M -$2.52M -44,450 -12%
KCM
33
Key Colony Management
Arkansas
$23.8M +$2.49M +44,058 +12%
Deutsche Bank
34
Deutsche Bank
Germany
$22.7M -$5.53M -97,710 -25%
PC
35
PointState Capital
New York
$21.1M -$4.25M -75,000 -21%
RSCM
36
Rock Springs Capital Management
Maryland
$20M +$5.21M +92,000 +55%
FHAM
37
Folger Hill Asset Management
New York
$19.9M +$14.6M +258,645 New
BIA
38
Biondo Investment Advisors
Pennsylvania
$19.5M -$114K -2,005 -0.8%
Geode Capital Management
39
Geode Capital Management
Massachusetts
$19.1M +$494K +8,724 +4%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$17.4M +$1.83M +32,355 +17%
Bank of Montreal
41
Bank of Montreal
Ontario, Canada
$15.9M -$1.19M -21,059 -9%
Norges Bank
42
Norges Bank
Norway
$15.1M +$3.55M +62,709 +47%
FCM
43
Frontier Capital Management
Massachusetts
$14.6M +$10.7M +189,746 New
MTIP
44
Magee Thomson Investment Partners
California
$13.6M +$2.39M +42,200 +31%
OAM
45
Oxford Asset Management
United Kingdom
$13.2M +$8.02M +141,695 +497%
BA
46
BlackRock Advisors
Delaware
$12.7M -$377K -6,657 -4%
TA
47
Teachers Advisors
New York
$12.6M +$6.26M +110,509 +206%
Janus Henderson Group
48
Janus Henderson Group
United Kingdom
$12.2M +$1.46M +25,708 +19%
CM
49
Castleark Management
Illinois
$11.1M +$8.16M +144,060 New
UBS AM
50
UBS AM
Illinois
$11M +$2.34M +41,354 +41%

PCRX Hedge Fund Activity: Q4 2015 in Review

214 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2015, worth a combined $3.29B — up 87% from $1.76B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new PCRX positions and 23 closed out — a net gain of 39 holders — while 70 added to existing stakes and 66 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $53.1M. The largest seller was Ameriprise, cutting an estimated $52.9M.

  • 214 institutional investors held Pacira BioSciences (PCRX) as of Q4 2015, up from 177 in Q3 2015.
  • Funds reported $3.29B of Pacira BioSciences stock for Q4 2015, up 87% quarter-over-quarter.
  • 62 funds opened new Pacira BioSciences positions in Q4 2015 and 23 closed out, a net change of +39 holders.
  • The largest Pacira BioSciences buyer in Q4 2015 was Fidelity Investments, an estimated $53.1M added.
  • The largest Pacira BioSciences seller in Q4 2015 was Ameriprise, an estimated $52.9M sold.

Based on aggregated 13F filings for Q4 2015.